Personalized medicine: The absence of 'model-changing' financial incentives

Personalized Medicine

Volumn 4, Issue 1, 2007, Pages 73-81

  Keeling, Peter ^a  

^a Diaceutics   (United Kingdom)

Author keywords

Amgen; Bayer; Bristol Myers Squibb; Cytyc Corp; Dako Metrika; Dasatinib; Diaceutics; Genentech; Genomic health; GlaxoSmithKline; Gleevec ; Herceptin ; Imatinib; Lab Corp; Lapatinib; Lilly; Metabolite; Monogram Biosciences; Nexavar ; Novartis; Onyx Pharmaceuticals; Panitumumab; Personalized Medicine Coalition; Pfizer's Sutent; Rituximab; Roche Rituxan ; Sorafenib; Sprycel ; Sunitinib; Trastuzumab; Tykerb

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIASTHMATIC AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIMIGRAINE AGENT; ANTIRHEUMATIC AGENT; ANTIVIRUS AGENT; ATORVASTATIN; CENTRAL NERVOUS SYSTEM AGENTS; CERIVASTATIN; CETUXIMAB; CISAPRIDE; CYCLOOXYGENASE 2 INHIBITOR; DASATINIB; IMATINIB; LAPATINIB; MIRAXION; NEUROLEPTIC AGENT; PANITUMUMAB; RITUXIMAB; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VECTIBIX; WARFARIN;

ALZHEIMER DISEASE; ARTICLE; ASTHMA; CANCER; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMMERCIAL PHENOMENA; COST BENEFIT ANALYSIS; COST CONTROL; DEPRESSION; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; DRUG UTILIZATION; FAMILY MEDICINE; FOOD AND DRUG ADMINISTRATION; GENETIC SCREENING; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HEALTH INSURANCE; HEART ARRHYTHMIA; HEPATITIS C; HUMAN; HUNTINGTON CHOREA; MEDICAL CARE; MIGRAINE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATENT; PATIENT CARE; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PHARMACOGENOMICS; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REIMBURSEMENT; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA;

EID: 33847010200     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.4.1.73     Document Type: Article

References (27)

1. The DNA Diagnosis Business. Business Communications Co, Inc., MA, USA (B-141R) (2005).
2. In Vitro Diagnostics Report, Technology Roadmap Project. Center for Economic Growth and the Lally School of Management and Technology (2004).
3. Shuster M: Planning for the Other Shoe to Drop - LabCorp. V. Metabolite. Burrill Personalized Medicine Report (2006).
4. Stallings SC, Witt WP, Crown WH et al.: A n economic framework for evaluating personalized medicine. POPI Working Abstracts WP-2004-03 (2003).
5. McWilliam A, Lutter R, Nardinelli C: Health care savings from personalizing medicine using genetic testing: the case of warfarin. AEI-Brookings Joint Center For Regulatory Studies. Working Paper 06-23 November (2006).
6. Ridge J: Reimbursement and coverage challenges associated with bringing emerging molecular diagnostics into the personalized medicine paradigm. Personalized Medicine 3 (3), 345-348 (2006).
7. Gillerman RG, Browning RA: Drug use inefficiency: a hidden source of wasted health care dollars. Anesth. Anaig. 91(4), 921-924 (2000).
8. McDonagh MS, Miller SA, Naden E: Costs and savings of investigational drug services. Am. J. Health Syst. Pharm. 57(1), 40-43 (2000).
9. Stroupe KT, Murray MD, Stump TE, Callahan CM: Association between medication supplies and healthcare costs in older adults from an urban healthcare system. J. Am. Geriatr. Soc. 48(7), 760-768 (2000).
10. Burrill: Personalized Medicine Report. The Burrill/BIO Personalized Medicine Meeting, October 18, 2005.
11. Kleinke JD: The price of progress: prescription drugs in the health care market. Health Affairs 20(5), 43-61 (2001).
12. Pharmaceutical Digest September 12, 2006.
13. The Case for Personalized Medicine. Personalized Medicine Coalition, Washington DC, USA (2006)
14. DiMasi JA: New drug development in the United States from 1963 to 1999. Clin. Pharmacol. Ther. 69, 286-296. (2001).
15. Kaiser Conversations on Health. Lilly, Washington DC, USA, May 10, 2006.
16. Keeling P: Research and development de mystified in pursuit of innovation. Pharmaceutical Business News, March 21 (1995).
17. Commercial Insight: Top 20 cancer therapeutics - new treatment paradigms transforming market outlook. July, 2006
18. Goldberg R: Vioxx-type danger and legal frivolity. The Washington Times, 24 August (2005).
19. Mattingly S: TechComm. Natl J. Tech. Commercialization 24 (2004).
20. Shah R: Can pharmacogenetics help rescue drugs withdrawn from the market. Pharmacogenomics 7, 889-908 (2006).
21. Commercial Insight: Top 20 cancer therapeutics - new treatment paradigms transforming market outlook. July (2006).
22. Vernon J: Economic and developmental considerations for pharmacogenomic technology. Pharmacoeconomics 24(4), 1 (2006).
23. Branca M, Keeling P: Pharmacogenomics and proteomics: enabling the practice of personalized medicine. American Association for Clinical Chemistry, Washington DC, USA, Chapter 9 (2006).
24. Hastie A, Lu H, Keeling P: Realizing the value of companion diagnostics - a model for demonstrating Dx contribution to positive Rx revenue. IBC Personalized Medicine Conference. Boston, MA, USA, 12-15 September, 2005.
25. Bio-Windhover: the Partnering Conference for Decision Makers. Washington, DC, 15-17 May, 2006.
26. The Value of Diagnostics Innovation, Adoption and Diffusion into Health Care. The Lewin Group (2005).
27. Keeling P: Integrating diagnostics and therapeutics for targeted therapy. Part 1: optimizing the co-marketing plan. Spectrum Decision Resources, April (2005).